|By PR Newswire||
|December 3, 2012 12:31 AM EST||
MILAN and COLLERETTO GIACOSA, Italy, December 3, 2012 /PRNewswire/ --
Mediolanum Farmaceutici SpA, a privately owned company that leads the Mediolanum Farmaceutici Group of companies, and Genovax srl, a private company which belongs to the portfolio of Eporgen Venture and was originated from the University of Genoa , announced the acquisition by Mediolanum of the global rights to GX301, Genovax's therapeutic vaccine to treat various types of cancer. The first clinical study with GX301 was successfully completed earlier this year in prostate and renal cancer patients. Further clinical studies are scheduled to be initiated in the next few months, and all future development and commercialization activities will be the responsibility of Mediolanum with the support of Genovax. Under the agreement, Genovax will receive upfront and milestone payments as well as royalties.
The acquisition of Genovax's innovative therapeutic vaccine for the treatment of various type of cancer is part of a strategy that we initiated since the late '90s and is a testament to our commitment to Research and Development", said Dr Rinaldo Del Bono, founder and President of Mediolanum Farmaceutici. "The acquisition of GX301 expands the interests of Mediolanum to a new therapeutic area (oncology). We look forward to advancing the development of the product through to its worldwide registration and make it available to cancer patients as soon as possible" added Dr Del Bono.
Dr Domenico Criscuolo, President of Genovax commented: "The agreement with Mediolanum is a remarkable achievement, which confirms the vision of all researchers who trusted in the therapeutic potential of GX301. In only four years Genovax's team was able to consolidate with clinical results the original idea and to attract the interest of Mediolanum, which will lead the further development work. My personal thanks to all Genovax team members, for their dedication and support to GX301 project, and a special acknowledgement to the memory of Silvano Fumero, who shared my enthusiasm for this project, and was instrumental for the foundation of Genovax."
Genovax was founded in March 2008 in Ivrea by Prof. Francesco Indiveri, Prof. Gilberto Filaci, Dr Daniela Fenoglio, Dr Giuseppe Balbi and Dr Domenico Criscuolo, with the financial support of Eporgen Venture. The science behind Genovax's technology was originated at the Centre of Excellence for Biomedical Research (CEBR), which is based at the University of Genoa. Konstantinos Efthymiopoulos, President of Eporgen Venture said: "We are delighted by this event which is the first major transaction of a company in our portfolio. It validates the vision of Eporgen's founder, the late Dr Silvano Fumero, and vindicates the 70 private shareholders of Eporgen who also believed in it and are nurturing innovation, Italian science and scientists and hope that new therapies will eventually emerge through their financial support. We would like to congratulate the Genovax team for bringing GX301 thus far and to wish every success in the further development of the product, hoping that it will become a life saving therapy for cancer patients."
Further notes for Editors:
GX301 is a telomerase-based vaccine against cancer, which completed in February 2012 the first phase I study in prostate and renal cancer patients with very promising results. The study was conducted in Italy and showed that GX301 was very well tolerated and that induced vaccine-specific immune response in all patients. Disease stabilisation was observed in about one third of the patients and overall survival was longer than expected. GX301 is composed by multiple peptides and adjuvants and is designed to induce potent immune responses that are specific for cancer cells through the activation of both CD4+ and CD8+ T lymphocytes. It is envisaged that GX301 may be useful also in other types of cancer and this will be explored in future clinical studies.
Genovax srl is a privately held company based in Colleretto Giacosa (Torino, Italy) and is focusing on the development of therapeutic vaccines against cancer, such as GX301, or chronic inflammatory diseases such as Systemic Lupus Erythematosus (SLE), where the lead product is GX101.
About Mediolanum Farmaceutici
Mediolanum was founded in 1972 by Dr Rinaldo Del Bono and its headquarters are located in Milan (Italy). It is a private pharmaceutical group that develops, manufactures, promotes and markets ethical pharmaceutical products (internally-developed, acquired or in-licensed) and herbal nutritionals. About 25 products are being commercialized by the Group, to treat cardiovascular, respiratory, inflammatory and dermatological disorders, infections, allergies, epilepsy, anemia and neuropathic pain. The Group currently employs around 570 people and its main commercial activities are concentrated in Italy and France, while sales in other countries are currently obtained through out-licensing and export activities.
About Eporgen Venture
Eporgen Venture (EV) is an Italian company, entirely funded by private, non-institutional investors, which is dedicated to seed capital investments in the area of life sciences. EV started its operations in 2005 and is based in the Bioparco "Silvano Fumero" in Colleretto Giacosa (Torino, Italy), where it created a portfolio of 11 companies (7 companies developing products and 4 companies developing technologies). These start-up companies are legally independent entities, controlled by EV, and are built around intellectual property that is being developed up to a proof-of-concept stage. The operating model of EV offers the virtues of the "asset-centric" investment model, but also the operating efficiencies of a small, virtual biotech with a centrally managed portfolio, guided by seasoned pharma and biotech executives. Since the start of its operations, EV has experienced a remarkable growth, by doubling the size of its investor base and of its portfolio of companies. Over the next six months EV is expected to complete further transactions and raise capital to advance the development of its assets.
President, Eporgen Venture SpA
SOURCE Eporgen Venture SpA
SYS-CON Events announced today that DatacenterDynamics has been named “Media Sponsor” of SYS-CON's 18th International Cloud Expo, which will take place on June 7–9, 2016, at the Javits Center in New York City, NY. DatacenterDynamics is a brand of DCD Group, a global B2B media and publishing company that develops products to help senior professionals in the world's most ICT dependent organizations make risk-based infrastructure and capacity decisions.
Apr. 29, 2016 05:45 AM EDT Reads: 2,388
SYS-CON Events announced today TMCnet has been named “Media Sponsor” of SYS-CON's 18th International Cloud Expo, which will take place on June 7–9, 2016, at the Javits Center in New York City, NY, and the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Technology Marketing Corporation (TMC) is the world's leading business-to-business and integrated marketing media company, servicing niche markets within the com...
Apr. 29, 2016 04:45 AM EDT Reads: 2,338
Between the mockups and specs produced by analysts, and resulting applications built by developers, there exists a gulf where projects fail, costs spiral, and applications disappoint. Methodologies like Agile attempt to address this with intensified communication, with partial success but many limitations. In his session at 18th Cloud Expo, Charles Kendrick, CTO & Chief Architect at Isomorphic Software, will present a revolutionary model enabled by new technologies. Learn how business and devel...
Apr. 29, 2016 03:45 AM EDT Reads: 1,634
Unless you don’t use the internet, don’t live in California, or haven’t been paying attention to the recent news… you should be aware that self-driving cars are on their way to becoming a reality. I have seen them – they are real. If you believe in the future reality of self-driving cars, then continue reading on. If you don’t believe in the future possibilities, then I am not sure what to do to convince you other than discuss the very real changes that will roll out with the consumer producti...
Apr. 28, 2016 09:45 PM EDT Reads: 360
If there is anything we have learned by now, is that every business paves their own unique path for releasing software- every pipeline, implementation and practices are a bit different, and DevOps comes in all shapes and sizes. Software delivery practices are often comprised of set of several complementing (or even competing) methodologies – such as leveraging Agile, DevOps and even a mix of ITIL, to create the combination that’s most suitable for your organization and that maximize your busines...
Apr. 28, 2016 08:45 PM EDT Reads: 1,718
In the rush to compete in the digital age, a successful digital transformation is essential, but many organizations are setting themselves up for failure. There’s a common misconception that the process is just about technology, but it’s not. It’s about your business. It shouldn’t be treated as an isolated IT project; it should be driven by business needs with the committed involvement of a range of stakeholders.
Apr. 28, 2016 07:30 PM EDT Reads: 1,762
New Relic, Inc. has announced a set of new features across the New Relic Software Analytics Cloud that offer IT operations teams increased visibility, and the ability to diagnose and resolve performance problems quickly. The new features further IT operations teams’ ability to leverage data and analytics, as well as drive collaboration and a common, shared understanding between teams. Software teams are under pressure to resolve performance issues quickly and improve availability, as the comple...
Apr. 28, 2016 07:15 PM EDT Reads: 2,367
The IoT has the potential to create a renaissance of manufacturing in the US and elsewhere. In his session at 18th Cloud Expo, Florent Solt, CTO and chief architect of Netvibes, will discuss how the expected exponential increase in the amount of data that will be processed, transported, stored, and accessed means there will be a huge demand for smart technologies to deliver it. Florent Solt is the CTO and chief architect of Netvibes. Prior to joining Netvibes in 2007, he co-founded Rift Technol...
Apr. 28, 2016 07:00 PM EDT Reads: 1,465
SYS-CON Events announced today that Enzu, a leading provider of cloud hosting solutions, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Enzu’s mission is to be the leading provider of enterprise cloud solutions worldwide. Enzu enables online businesses to use its IT infrastructure to their competitive advantage. By offering a suite of proven hosting and management services, Enzu wants companies to foc...
Apr. 28, 2016 05:30 PM EDT Reads: 820
Many private cloud projects were built to deliver self-service access to development and test resources. While those clouds delivered faster access to resources, they lacked visibility, control and security needed for production deployments. In their session at 18th Cloud Expo, Steve Anderson, Product Manager at BMC Software, and Rick Lefort, Principal Technical Marketing Consultant at BMC Software, will discuss how a cloud designed for production operations not only helps accelerate developer...
Apr. 28, 2016 05:00 PM EDT Reads: 991
Join IBM June 8 at 18th Cloud Expo at the Javits Center in New York City, NY, and learn how to innovate like a startup and scale for the enterprise. You need to deliver quality applications faster and cheaper, attract and retain customers with an engaging experience across devices, and seamlessly integrate your enterprise systems. And you can't take 12 months to do it.
Apr. 28, 2016 04:45 PM EDT Reads: 1,724
This is not a small hotel event. It is also not a big vendor party where politicians and entertainers are more important than real content. This is Cloud Expo, the world's longest-running conference and exhibition focused on Cloud Computing and all that it entails. If you want serious presentations and valuable insight about Cloud Computing for three straight days, then register now for Cloud Expo.
Apr. 28, 2016 04:30 PM EDT Reads: 1,617
Based on the open source Cloud Foundry technology, IBM Bluemix is an open-standard, cloud-based platform for building, managing, and running applications of all types such as web, mobile, Big Data, and new smart devices. Bluemix abstracts and hides most of the complexities that are associated with hosting and managing cloud-based applications. As an application developer, you can focus on developing your application without having to manage the infrastructure that is required to host it. For mob...
Apr. 28, 2016 04:00 PM EDT Reads: 937
The proper isolation of resources is essential for multi-tenant environments. The traditional approach to isolate resources is, however, rather heavyweight. In his session at 18th Cloud Expo, Igor Drobiazko, co-founder of elastic.io, will draw upon their own experience with operating a Docker container-based infrastructure on a large scale and present a lightweight solution for resource isolation using microservices. He will also discuss the implementation of microservices in data and applicat...
Apr. 28, 2016 04:00 PM EDT Reads: 1,638